Abstracts tagged "citrullination"

Abstract Number: 0045 • ACR Convergence 2024
Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins
Khushali Trivedi¹, Clarissa Klenke², Jun Kim¹, Jeba Atkia Maisha², Alina Sememenko¹, XIAOBO MENG², Mario Navarrete¹, Hani El-Gabalawy² and Liam O'Neil², ¹University of Manitoba, Winnipeg, Canada, ²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
Abstract Number: 0046 • ACR Convergence 2024
Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies
Jeba Atkia Maisha¹, Alina Sememenko², Jun Kim², Mario Navarrete², XIAOBO MENG¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Rheumatoid Arthritis (RA) begins after a prolonged preclinical phase which is marked by the development of RA antibodies, typically against citrullinated proteins (ACPA). The…
Abstract Number: 0062 • ACR Convergence 2024
Pro-Fibrotic Effects of Malondialdehyde-Acetaldehyde-Adducted and/or Citrullinated Proteins on Macrophages and Human Lung Fibroblasts
Lauren Klingemann¹, Nozima Aripova¹, Nigina Aripova², Michael Duryee¹, Carlos Hunter¹, Jill Poole¹, Bryant England¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²WUSTL, St. Louis, MO
Background/Purpose: Clinically evident rheumatoid arthritis-associated interstitial lung disease (RA-ILD) affects approximately 10-15% of patients with rheumatoid arthritis (RA) and accounts for the most overrepresented cause…
Abstract Number: 0065 • ACR Convergence 2024
Evidence of Membranolytic Targeting and Intracellular Citrullinationin Neutrophils Isolated from Patients with Rheumatoid Arthritis
Neela Fatemeh Moadab¹, Tal Gazitt², Rayan Najjar¹, Ethan Le¹, J Lee Nelson³, Vijay Joshua⁴, Keith Elkon¹, Caroline Grönwall⁴ and Tomas Mustelin¹, ¹University of Washington, Seattle, WA, ²Carmel Hospital, Haifa, Israel, ³University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) are diagnostic for rheumatoid arthritis (RA). The antigens recognized by these autoantibodies are produced by protein arginine deiminases (PADs), particularly…
Abstract Number: 1846 • ACR Convergence 2024
Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis
Amy Anderson¹, Henrique de Paula Lemos¹, Hendrik Nel², Sofia Sorbet Santiago¹, Fiona Rayner³, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Jasmine Sim¹, Andrew Melville⁴, Stefan Siebert⁴, Iain McInnes⁵, Carl Goodyear⁴, Catharien Hilkens¹, Andrew Filer⁶, Karim Raza⁶, Christopher Buckley⁷, Hugh Reid⁸, Kenneth Baker¹, Arthur Pratt³, Jamie Rossjohn⁸, Ranjeny Thomas⁹ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁵University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁶Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁷Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁸Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, ⁹University of Queensland, Brisbane, Australia
Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…
Abstract Number: 1858 • ACR Convergence 2024
Co-modification of Citrullinated Proteins with Malondialdehyde-Acetaldehyde Leads to Amplified T Cell Responses and Increased Disease-specific Autoantibody Concentrations
Breanna Butler¹, Wenxian Zhou², Michael Duryee¹, Nozima Aripova¹, Engle Sharp¹, Carlos Hunter¹, Bridget Kramer¹, Harlan Sayles¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹, Joshua Baker³, Andreas Reimold⁴, Gail Kerr⁵ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴Dallas VA Medical Center, Dallas, TX, ⁵Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is highly specific to rheumatoid arthritis (RA). Beyond citrullination, other post-translational protein modifications including malondialdehyde-acetaldehyde (MAA) are targeted by T…
Abstract Number: L08 • ACR Convergence 2023
Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation
Leonie Middelink¹, Renato Chirivi², Helmuth van Es², Eric Meldrum², Peter van Zandvoort², Tirza Bruurmijn², Matthijs Moerland³ and Patrick Round², ¹Middelinc., Utrecht, Netherlands, ²Citryll BV, Oss, Netherlands, ³CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Traps (NETs) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases such as Rheumatoid arthritis (RA) Hidradenitis suppurativa (HS),…
Abstract Number: 1727 • ACR Convergence 2023
Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice
Sheri Saunders, Garth Blackler, Patti Kiser, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada
Background/Purpose: Most rheumatoid arthritis (RA) patients express autoantibodies to post-translationally modified antigens, including citrullinated and homocitrullinated (also known as carbamylated) peptides. Homocitrulline and citrulline are…
Abstract Number: 1742 • ACR Convergence 2023
Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA
Rachna Talluri¹, Sudeshna Sen², Timothy Wilson³, Adam Savage⁴, Mark Gillespie⁴, Tom Bumol⁴, Marie Feser¹, Jill Norri⁵, Michael Holer¹, kevin Deane¹, Paul Thompson² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Thomas Jefferson University, Philadelphia, PA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Denver, CO
Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
Abstract Number: 1748 • ACR Convergence 2023
Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies
S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
Abstract Number: 1764 • ACR Convergence 2023
Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Breanna Butler¹, Jill Poole¹, Michael Duryee¹, Nozima Aripova¹, Carlos Hunter¹, Bridget Kramer¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
Abstract Number: 1775 • ACR Convergence 2023
The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline
Jack Mordeson¹, Nozima Aripova¹, Michael Duryee¹, James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted R Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90%…
Abstract Number: 0045 • ACR Convergence 2023
Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases
Min Yang¹, song feng¹, yuling wen¹, Xiaoming ren¹, Huijuan Li¹, lili yao¹, Zhi xie² and Wenge zhong¹, ¹Regor Therapeutics, Shanghai, China, ²Regor Pharmaceuticals, Inc., San Francisco, CA
Background/Purpose: Protein arginine deiminases (PAD) 4 is an enzyme that catalyzes the conversion of protein-embedded arginine to citrulline. It is essential for neutrophil extracellular traps…
Abstract Number: 0050 • ACR Convergence 2023
Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease
Maarten van der Linden¹, Sangeeta Kumari¹, Daphne Montizaan¹, Stephanie van Dalen¹, Annemarie Kip¹, Martyn FOSTER², Inge Reinieren¹, Elsa Neubert³, Luise Erpenbeck⁴, Tirza Bruurmijn¹, Peter van Zandvoort¹, Paul Vink¹, Eric Meldrum⁵, Helmuth van Es¹ and Renato Chirivi¹, ¹Citryll BV, Oss, Netherlands, ²Experimental Pathology Consultancy, Benfleet, United Kingdom, ³Leiden Academic Centre for Drug Research, Leiden, Netherlands, ⁴University Medical Center Münster, General Dermatology and Venereology, Münster, Germany, ⁵Citryll BV, Basel, Switzerland
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of multiple inflammatory and autoimmune diseases (Chirivi et al., 2021; DOI: 10.1038/s41423-020-0381-3). Targeting the NETosis pathway…
Abstract Number: 0423 • ACR Convergence 2023
Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis
Sara Charmsaz¹, Jeff Tracy¹, Elizabeth Whalen¹, John Bui¹, Anne-Renee van der Vuurst de Vries¹, Vivianne Malmström² and Michelle Blake¹, ¹Sonoma Biotherapeutics, Seattle, WA, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and despite many therapeutic options, an unmet medical need persists for novel therapies…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].